Picture Kentro Design Corporate and Web Design Berlin 650x65px
Collaboration › Details

Evotec–Leucadia: investor conference, 201611 supply service Evotec AG presents at Jefferies 2016 Global Healthcare Conference London


Period Period 2016-11-17
Region Region London, Greater London
  Country United Kingdom (GB)
  Predecessor Evotec–Leucadia: investor conference, 201606 supply service Evotec AG presents at Jefferies 2016 Global Healthcare Conference NYC
  Successor Evotec–Leucadia: investor conference, 201711 supply service Evotec AG presents at Jefferies 2017 Global Healthcare Conference London
Organisations Partner, 1st Evotec AG (FSE: EVT, TecDAX)
  Today Evotec SE (FSE: EVT, MDA X/TecDAX)
  Group Evotec (Group)
  Partner, 2nd Jefferies LLC
  Group Leucadia (Group)
Products Product Jefferies 2016 London Healthcare Conference
  Product 2 drug discovery services
Persons Person Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH)
  Person 2 Hansen, Gabriele (Evotec 201404 VP Corporate Communications + Investor Relations)

Evotec AG. (11/14/16). "Press Release: Evotec to Present at Two Upcoming IR Conferences in November". Hamburg.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will present at the Jefferies 2016 Global Healthcare Conference in London, UK, and at the German Equity Forum 2016, Frankfurt, Germany.

Jefferies 2016 Global Healthcare Conference in London, UK
Date: Thursday, 17 November 2016, 04.00 pm GMT (05.00 pm CET)
Venue: London, UK
Presenter: Enno Spillner, Chief Financial Officer of Evotec AG

The PDF version and the direct link to the webcast of the presentation will be provided at

German Equity Forum 2016 in Frankfurt, Germany
Date: Tuesday, 22 November 2016, 10.00 am CET
Venue: Sheraton Frankfurt Airport Hotel and Conference Center, Frankfurt, Germany
Presenters: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG; Enno Spillner, Chief Financial Officer of Evotec AG


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis. For additional information please go to


Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:

Record changed: 2017-07-02


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Evotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top